View Clinical Trial (Medical Research Study)

Use of Sildenafil (Viagra) to Alter Fatigue, Functional Status and Impaired Cerebral Blood Flow in Patients With CFS - NCT00598585-90059(Clinical Trial 199122)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  Los Angeles
State:  
CA
Zip Code: 90059
Conditions: Chronic Fatigue Syndrome
Purpose: Use of Viagra to Alter Symptoms in Patients with Chronic Fatigue Syndrome (CFS)
Study summary: Use of Sildenafil (Viagra) to Alter Fatigue, Functional Status and Impaired Cerebral Blood Flow in Patients with Chronic Fatigue Syndrome.
Criteria: Inclusion Criteria: - Patients meeting the CDC definition of CFS. - All races, ethnicities, socio-economic status (SES), and gender - Age greater than 18 (because of concerns about radioactivity, we and the Cedars-Sinai and Harbor-UCLA IRBs have decided not to enroll subjects below the age of 18). - Age less than 50. Because of concern of sildenafil exacerbating coronary artery disease, we will only enroll patients younger than 50. - Able to provide informed consent. - Willingness to be off all medicines and supplements for 3 weeks prior to the study. - Patients with psychiatric disorders (see below) will be included, if they could be off their medications, and if their psychiatric diagnosis clearly occurred after their fatigue symptoms began. - Patients with concurrent fibromyalgia will be allowed to participate if the meet diagnostic criteria for CFS. Exclusion Criteria: - Disabilities that would prevent them from participating in the study. - Current use of prescription medicines (starting at 3 weeks prior to the study) and supplements (starting at 1 weeks prior to the study) except acetaminophen or aspirin. This includes herbal supplements and vitamins. - Existing medical illnesses, such as heart disease, hypertension, cancer, rheumatological diseases, endocrinopathies or hormone replacement therapy, seizure disorders, severe obesity (BMI > 32 kg/m2), - Severe psychiatric disorders including bipolar disorder, schizophrenia, dementia and previous or current diagnosis of alcohol or substance abuse within the past year. Patients with depression of such severity as to warrant treatment with anti-depressants will be excluded. - Current abuse of illicit drugs or heavy ethanol use. - Pregnant women will be excluded because of radioactivity exposure from the SPECT scans. - Abnormal EKG - Abnormal CBC, blood chemistries, thyroid function tests, and HIV, ANA, RF and ESR tests.
Study is available at: Charles Drew University of Medicine and Science
Los Angeles, CA 90059
United States

Primary Contact:
Erik Zuckerbraun, M.D.
Email: erzucker@cdrewu.edu
Phone: 310-668-8754

Secondary Contact:
Erik Zuckerbraun, M.D.
Email: erikzuckerbraun@cdrewu.edu
Phone: 310.668.8754
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: March 22, 2011
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.